Amarin Corp. PLC (AMRN) Hits New 52-Week High at $3.46
Amarin Corp. PLC (NASDAQ:AMRN)’s share price hit a new 52-week high on Monday . The company traded as high as $3.46 and last traded at $3.21, with a volume of 2,484,294 shares. The stock had previously closed at $3.33.
A number of equities analysts recently weighed in on AMRN shares. Zacks Investment Research raised shares of Amarin Corp. PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, April 26th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Amarin Corp. PLC in a research note on Monday, May 9th. Finally, Jefferies Group started coverage on shares of Amarin Corp. PLC in a research note on Thursday, May 12th. They issued a “buy” rating and a $3.50 target price for the company.
The company has a 50-day moving average price of $2.36 and a 200-day moving average price of $1.83. The firm’s market capitalization is $603.22 million.
Amarin Corp. PLC (NASDAQ:AMRN) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $32.82 million for the quarter, compared to analyst estimates of $29.97 million. During the same quarter last year, the firm posted ($0.15) EPS. Amarin Corp. PLC’s revenue for the quarter was up 85.4% on a year-over-year basis. Analysts anticipate that Amarin Corp. PLC will post ($0.53) earnings per share for the current year.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.